OBJECTIVE: To describe the challenges to blinding in behavioral interventions, specifically those for asymptomatic medical conditions, where the intervention is through counseling, and to provide recommendations for achieving blinding in behavioral randomized controlled trials (RCTs). METHODS: This paper reviews the challenges of preserving blinding in behavioral RCTs with a focus on interventions for asymptomatic medical conditions. This is illustrated using a case study of an ongoing behavioral intervention to improve hypertension control. RESULTS: In contrast to easily keeping study investigators and participants masked to treatment assignment through the use of identical pills or sham treatments, the need to have differing levels of blinding among study personnel and participants in randomized behavioral intervention trials is presented. Recommendations for achieving this are provided. CONCLUSIONS: Despite the challenges inherent in behavioral interventions, it is possible to achieve differing levels of blinding across study personnel and participants to minimize bias and generate valid data in RCTs that test interventions for asymptomatic medical conditions such as hypertension. Modifications may be needed for RCTs in symptomatic medical conditions. PRACTICE IMPLICATIONS: Researchers designing behavioral RCTs should be aware of the challenges to blinding all staff and study participants, and plan to have procedures in place to standardize outcome data collection and intervention delivery without compromising the varying levels of blinding. The challenges and recommendations described may need modifications in behavioral intervention studies for symptomatic conditions.
OBJECTIVE: To describe the challenges to blinding in behavioral interventions, specifically those for asymptomatic medical conditions, where the intervention is through counseling, and to provide recommendations for achieving blinding in behavioral randomized controlled trials (RCTs). METHODS: This paper reviews the challenges of preserving blinding in behavioral RCTs with a focus on interventions for asymptomatic medical conditions. This is illustrated using a case study of an ongoing behavioral intervention to improve hypertension control. RESULTS: In contrast to easily keeping study investigators and participants masked to treatment assignment through the use of identical pills or sham treatments, the need to have differing levels of blinding among study personnel and participants in randomized behavioral intervention trials is presented. Recommendations for achieving this are provided. CONCLUSIONS: Despite the challenges inherent in behavioral interventions, it is possible to achieve differing levels of blinding across study personnel and participants to minimize bias and generate valid data in RCTs that test interventions for asymptomatic medical conditions such as hypertension. Modifications may be needed for RCTs in symptomatic medical conditions. PRACTICE IMPLICATIONS: Researchers designing behavioral RCTs should be aware of the challenges to blinding all staff and study participants, and plan to have procedures in place to standardize outcome data collection and intervention delivery without compromising the varying levels of blinding. The challenges and recommendations described may need modifications in behavioral intervention studies for symptomatic conditions.
Authors: Heather M Johnson; Lisa Sullivan-Vedder; KyungMann Kim; Patrick E McBride; Maureen A Smith; Jamie N LaMantia; Jennifer T Fink; Megan R Knutson Sinaise; Laura M Zeller; Diane R Lauver Journal: Contemp Clin Trials Date: 2019-01-21 Impact factor: 2.226
Authors: Almudena Carneiro-Barrera; Francisco J Amaro-Gahete; Alejandro Guillén-Riquelme; Lucas Jurado-Fasoli; Germán Sáez-Roca; Carlos Martín-Carrasco; Gualberto Buela-Casal; Jonatan R Ruiz Journal: JAMA Netw Open Date: 2022-04-01
Authors: Marina Serper; Daniela P Ladner; Laura M Curtis; Sumi S Nair; Scott I Hur; Mary J Kwasny; Bing Ho; John Friedewald; Peter P Reese; Michael M I Abecassis; Michael S Wolf Journal: Contemp Clin Trials Date: 2021-01-27 Impact factor: 2.226
Authors: Maria Antonia Rodriguez; Binhuan Wang; Sangmin Hyoung; Jennifer Friedberg; Judith Wylie-Rosett; Yixin Fang; John P Allegrante; Stuart R Lipsitz; Sundar Natarajan Journal: Hypertension Date: 2021-05-12 Impact factor: 10.190
Authors: Liz Steed; Ratna Sohanpal; Adam Todd; Vichithranie W Madurasinghe; Carol Rivas; Elizabeth A Edwards; Carolyn D Summerbell; Stephanie Jc Taylor; R T Walton Journal: Cochrane Database Syst Rev Date: 2019-12-06
Authors: Edward Zimbudzi; Clement Lo; Marie L Misso; Sanjeeva Ranasinha; Peter G Kerr; Helena J Teede; Sophia Zoungas Journal: Syst Rev Date: 2018-06-13